Evidence mapPaperPMID 40453084Full record

ReviewFrontiers in immunology2025

Recent advances in regulatory immune cells: exploring the world beyond Tregs.

Peng Shi, Yi Yu, Hongwei Xie, Xiaofang Yin, Xue Chen, Yongfei Zhao, Hai Zhao

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peng ShiDepartment of Emergency, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yi YuDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Hongwei XieDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xiaofang YinDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xue ChenDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yongfei ZhaoDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Hai ZhaoDepartment of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory immune cells are pivotal in maintaining immune homeostasis and modulating immune responses to prevent pathologies. While T regulatory cells (Tregs) are extensively recognized for their immunosuppressive roles, emerging subsets of regulatory cells, including regulatory CD8+ cells (CD8+Tregs) regulatory B cells (Bregs), myeloid-derived suppressor cells (MDSCs), regulatory dendritic cells (DCregs), regulatory innate lymphoid cells (ILCregs), and regulatory natural killer cells (NKregs), are garnering increased attention. This review delves into the phenotypic characteristics, mechanisms of action, and immune-regulatory functions of these lesser-known but crucial immune cell subsets. The review provides a comprehensive examination of each cell type, detailing their origins, unique functionalities, and contributions to immune homeostasis. It emphasizes the complex interplay among these cells and how their coordinated regulatory activities influence immune responses in diverse pathological and therapeutic contexts, including autoimmunity, cancer immunotherapy, chronic inflammation, and transplant tolerance. By unraveling these mechanisms, the review outlines novel therapeutic avenues, such as targeting these regulatory cells to modulate immune activity and enhance precision medicine approaches. The future of immunotherapy and immune modulation lies in leveraging the expanded knowledge of these regulatory immune cells, presenting challenges and opportunities in clinical applications.

Indexed as

B-Lymphocytes, RegulatoryT-Lymphocytes, RegulatoryAnimalsDendritic CellsHomeostasisHumansImmune ToleranceImmunity, InnateImmunotherapyKiller Cells, NaturalMyeloid-Derived Suppressor CellsBregsCD8+ TregsDCregsILCregsMDSCNKregsTregs

Identifiers

PMID40453084
PMCPMC12122350

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.